Business
Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer
SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Mark A. Wilson as Chief Legal Officer. Mr. Wilson is an accomplished pharmaceutical and biotech executive with more than 25 years of experience across intellectual property, corporate legal, strategic collaborations and corporate governance matters. “We are
About this update from Septerna, Inc.
[{"type":"image","alt":"Septerna, Inc.","displaySize":"","headline":null,"caption":"Septerna, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/d2f80cf1ee51689cfd5290865894d732"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/IfFfBXl5FaGoxi.1VkTugg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/d2f80cf1ee51689cfd5290865894d732","width":300,"height":63}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Mark A. Wilson as Chief Legal Officer. Mr. Wilson is an accomplished pharmaceutical and biotech executive with more than 25 years of experience across intellectual property, corporate legal, strategic collaborations and corporate governance matters.","length":491,"tagName":"p"},{"type":"text","content":"“We are thrilled to welcome Mark to the team,” said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. “His deep expertise across intellectual property strategy and corporate legal matters will be instrumental as we continue to strengthen our governance framework and maximize the value of our portfolio and proprietary Native Complex Platform™. Mark’s leadership will be vital as we scale the capabilities needed to execute on our long-term strategy and deliver new medicines for patients.”","length":520,"tagName":"p"},{"type":"text","content":"“Septerna represents an extraordinary opportunity to be part of a company that is transforming GPCR drug discovery,” said Mr. Wilson. “I am excited to join this talented team and contribute to the advancement of innovative therapies that have the potential to make a meaningful difference for patients.”","length":303,"tagName":"p"},{"type":"text","content":"Mr. Wilson joins Septerna from Nektar Therapeutics, where he most recently served as Senior Vice President and Chief Legal Officer. In this role, he served as chief attorney and senior manager for the legal, human resources, and information technology departments, and was a member of the company’s executive committee. During his tenure, Mr. Wilson served as lead attor...